August 2022 ERS/ESC Guidelines Flashcards

1
Q

Top two causes of PH in overall population

A

Overall, most common cause of elevated PA pressures

(1) L. sided heart disease
(2) Lung disease, mostly COPD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Top three (in order) most common causes of group I PAH

A

Group I PAH etiologies

1st- IPAH (idiopathic)
2nd- CTD-related
3rd- Congenital heart disease
4th- Portopulmonary (PoPH)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Prevalence of PH in severe L-sided (mitral, aortic) valvular disease

A

Very high
-severe, symptomatic mitral valve disease: 60-70% have PH
-about 50% in severe symptomatic aortic stenosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Key echocardiogrpahic probability of PH

A

Peak TRV (tricuspid regurg velocity) as the key variable for assigning echocardiographic probability of PH (and not estimated sPAP)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Guideline recommended use of CPET in patients depending on TTE findings

A

Consider CPET to further determine likelihood of PH in symptomatic patients with intermediate echocardiographic probability of PH- IIb recommendation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Utility of DETECT algorithm

A

Algorithm to identify asymptomatic systemic sclerosis patients with PAH.
-systemic sclerosis > 3 years with FVC >= 40% and DLCO < 60%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Difference in risk stratification at time of diagnosis vs. during follow-up

A

Risk stratification

At time of diagnosis: three-strata model (low, intermediate, high) based on hemodynamics

At f/u: four-strata model (low, intermediate-low, intermediate-high, and high risk based on WHO-FC, 6MWD, BNP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Guideline rec for when to
(a) refer for transplant eval
(b) list for transplant

A

Grade I Recommendations:

(a) Refer for transplant evaluation: potentially eligible candidates with inadequate response to oral combination therapy = intermediate-high or high-risk or REVEAL risk > 7

(b) List: present with high risk of death or REVEAL >=10 despite optimized medical therapy (including SQ or IV prostacyclins)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Guideline cutoffs for recommendation of ASD closure based on PVR

A

A little wishy-washy especially once PVR above 3

-grade I rec to close ASD/VSD/PDA if PVR < 3
-consider shunt closure of ASD/VSD/PDA if PVR 3-5 and if PVR <5 with PAH treatment
-grade III rec to not close ASD if PVR > 5

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Maneuvers to consider during RHC for patients with borderline PAWP and c/f HFpEF

A

IIb rec: consider exercise or fluid challenge to uncover post-capillary PH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Change in guidelines for use of diagnostic RHC in patients for suspected PH in patients with lung disease

A

2015- RHC not recommended for group III unless thought to have therapeutic consequence (clinical trial, c/f group I)

2022- grade I rec for RHC in patients with lung disease and suspected PH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Recommendation for use of inhaled treprostinil

A

Grade IIb recommendation to consider inhaled treprostinil for pts with PH associated with ILD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

2022 definition of exercise PH

(a) Caveat

A

mPAP/CO slope between rest and exercise > 3 mmHg/L/min

(a) Caveat- defines an abnormal hemodynamic response to exercise but does not differentiate pre and post-capillary cause

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Ratio to differentiate pre and post-capillary causes of exercise PH?

A

Definition of exercise PH: mPAP/CO slope between rest and exercise > 3 mmHg/L/min
^doesn’t differentiate pre and post capillary

“PAWP/CO with threshold > 2 may best differentiate between pre and post capillary causes of exercise PH”
-PAWP/CO < 2 for pts with early pulmonary vascular disease
-HfpEF or dynamic MR and normal PAWP at rest usually show steep increase in mPAP and PAWP (and PAWP/CO slope) during exercise

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Limitation of exercise doppler echocardiography in diagnosis of PH

A

In most cases increased in sPAP during exercise are 2/2 diastolic LV dysfunction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Strengths/weaknesses of normal perfusion scan for excluding CTEPH

A

Normal perfusion scan excludes CTEPH with a negative predictive value of 98% in ABSENCE of parenchymal lung disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Combination of which three parameters on CT chest are highly predictive of PH diagnosis

A
  1. PA diameter >= 30mm
  2. RVOT wall thickness >= 6mm
  3. Septal deviation >= 140 degrees (or RV/LV ratio >= 1)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

TRV cutoffs used for risk stratification of PH

A

TRV <= 2.8 m/s without other echo signs of PH = PH low probability

TRV 2.9-3.4 m/s without other echo signs of PH = PH probability intermediate
TRV 2.9-3.4 m/s with other echo signs of PH = PH probaility high

TRV > 3/4 m/s regardless of presence of other echo PH signs = PH probability high

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

When is vasoreactivity testing indicated?

A

Pts with idiopathic, hereditary, drug-induced PH

Recommended against vasoreactivity testing in pts with suspected etiology NOT idiopathic, hereditary, drug-induced

20
Q

Contraindications to RHC

A

-acute infection
-mechanical R heart valve or triclip (for tx of TR)
-tumor or thrombus in RA or RV
-recently implanted (less than 1 month) pacemaker

21
Q

Normal values for

(a) sPAP
(b) dPAP
(c) mPAP

A

Normal values

(a) sPAP 15-30 mmHg
(b) dPAP 4-12 mmHg
(c) mPAP 8-20 mmHg

22
Q

Normal values for

(a) PVR
(b) TPR

A

(a) PVR = (mPAP - PCWP) / CO, normal 0.3-2.0 WU
(b) TPR = mPAP / CO, normal < 3 WU

WU x 80 ~~ Dynes/s/cm^-5
(a) Normal PVR = 0.3-2.0 WU = 30-160 Dynes/
(b) Normal TPR < 3 WU < 240 Dynes/

23
Q

Mixed venous cutoff to consider compartmental oximetry to exclude intracardiac shunt

A

If SvO2 > 75% (PA sat over 75%) on room air- do compartmental oximetry to exclude intracardiac shunt

24
Q

Formula for pulmonary artery compliance

A

C = V/P

PAC = Stroke volume / (sPAP-dPAP)

25
Q

Normal value for pulmonary artery compliance

A

PA compliance = stroke volume / (sPAP-dPAP)

Normal value:
RV (and LV) stroke volume: 60-100ml
Normal PAC > 2.3 ml/mmHg (>3 some say, <2 is def bad)

26
Q

Definition of positive vasoreactivity

A

Reduction in mPAP >= 10mmHg to reach absolute value <= 40mmHg with increased or unchanged CO

27
Q

Guideline rec for when to refer for lung transplant

A

Inadequate response to oral combination therapy indicated by intermediate-high or high-risk or by REVEAL risk score > 7

28
Q

Guideline rec for when to list for lung transplant

A

High risk of death or REVEAL >= 10 despite optimized medical therapy

29
Q

PVR cutoffs in pts with intracardiac shunt where

(a) shunt closure recommended
(b) shunt closure considered
(c) shunt closure not recommended

A

PVR cutoffs for shunt closure

30
Q

Guideline first line medication for pts with Eisenmenger syndrome

A

Bosentan recommended in symptomatic pts with Eisenmenger syndrome to improve exercise capacity

31
Q

Group III medications: guideline recs

(a) inhaled treprostinil
(b) ambrisentan
(c) riociguat

A
32
Q

Guidelines- when to consider PDE5i in pts w. ILD-PH

A

New in 2022: consider PDE5i in pts with severe ILD-PH (IIb, level C evidence) but not recommended to use PDE5i in pts with ILD and non-severe PH

33
Q

Definition of exercise PH

(a) Pitfall

A

mPAP / CO slope > 3
-so need to exercise, repeat mPAP and thermodilution CO measurements
-concept: mPAP rises out of proportion to increase in CO

(a) Doesn’t differentiate pre and post capillary cause of elevated mPAP (also positive in HFpEF/post-capillary causes)

34
Q

How idiopathic are subgrouped in 2022 guidelines

A

Different from 2015- new subgroups in idiopathic differentiated by non-responders vs. acute responders

35
Q

Why TRV used over sPAP as the key variable for assigning echocardiographic probability of PH

A

sPAP inaccuracy given inaccuracy of RA pressure estimation and amplification of measurement errors by using derived variables

36
Q

Describe EKG findings of RVH

A
37
Q

Describe RV strain pattern on EKG as seen on this EKG

A

ST depressions and T-wave inversions in R precordial leads (V1-V4) and inferior leads (II, III, aVF)

Other features of RVH present on this EKG: dominant R wave in V1, R axis deviation

38
Q

Explain this TTE finding suggestive of elevated PA pressure

A

RVOT velocity recording
-pulse wave doppler through RVOT (modified PSAX), mid-systolic notching suggests elevated PAP

39
Q

Negative predictive value of normal V/Q scan for CTEPH

A

98%

40
Q

Explain the following TTE parameters in the assessment of PH:

RVOT acceleration time cut off

A

RVOT acceleration time- pulse wave doppler through high PSAX. Higher the PA pressure, slower acceleration time (b/c more after load)

RVOT AT < 105ms and mid-systolic notch indicative of pre-capillary PH

41
Q

Explain the following TTE parameters in the assessment of PH:

RV fractional area change

A

RV fractional area change, change in area of the RV from diastole to systole, normal > 35% change

< 35% change suggestive of PH (elevated PA pressures)

42
Q

Differentiate TAPSE and TDI

A

TAPSE- M-mode through lateral tricuspid annulus to measure wall movement, abnormal < 18mm

TDI- decreased movement of tricuspid valve annulus muscle during systole (< 9.5 cm/s is abnormal)

43
Q

How peak TRV is measured

A

Peak tricupid valve regurgitation (preferred value for assigning TTE probability of PH) measured by continuous doppler through tricuspid valve

Under x-axis (away from probe) will see flow- take peak velocity of this. Then used modified bernoullis (dP = 4 x v^2) to estimate pressure gradient from max velocity

44
Q

How sPASP is calculated on TTE

A
  1. RA pressure via IVC size and collapsibility
  2. RV pressure by TR pressure gradient (dP = 4 x v^2)
    v = peak TR jet velocity

EX:

sPAP = TR pressure gradient + estimated RAP

45
Q

3 CT chest features of PH (not CTEPH but PH more specifically R heart stuff)
Hint: PA/RV stuff not parenchymal

A
  1. Enlarged PA:aorta ratio > 0.9, PA diameter > 30mm (3cm)
  2. RVOT wall thickness > 6mm
  3. RV:LV ratio >1
46
Q

Guideline lab workup to send for autoimmune comorbidities

A
  1. ANA
  2. Anti-centromere (CREST)- not the same as anti-SCl 70 (topoisomerase more seen in systemic sclerosis)
  3. Anti-Ro (SJogrens)
47
Q
A